Harmony Biosciences reports record Q2 WAKIX sales of $261M
Harmony Biosciences Holdings, Inc. reported preliminary Q2 2026 net product revenue of $261 million for WAKIX, a 30% YoY increase, and reaffirmed its full-year 2026 guidance of $1.0 billion to $1.04 billion. CFO Glenn Reicin stepped down effective July 16, 2026, with Stephen Mollichella appointed as Interim Principal Financial Officer.
*this image is generated using AI for illustrative purposes only.
Harmony Biosciences Holdings, Inc. announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX (pitolisant) of approximately $261 million. This figure represents a new quarterly revenue record for the company, marking 30% year-over-year growth and 21% sequential growth from Q1 2026. The company attributed the performance to strong demand and disciplined commercial execution, underscoring sustained momentum through the first half of 2026.
Based on its first-half performance and current business trends, Harmony Biosciences reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion. "Our record quarterly results reflect the continued strength of the WAKIX franchise and sustained momentum across the business," said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. "Demand remains strong, our commercial execution continues to deliver results and, based on our performance through the first half of the year, we remain confident in our ability to achieve full-year net revenue of $1.0 billion to $1.04 billion."
Financial Highlights
| Metric | Q2 2026 Value | Growth |
|---|---|---|
| Net Product Revenue | $261 million | 30% YoY |
| Sequential Growth | 21% | Q2 over Q1 |
| FY 2026 Guidance | $1.0 billion – $1.04 billion | Reaffirmed |
Leadership Transition
Harmony Biosciences announced a transition in its financial leadership. Chief Financial Officer Glenn Reicin stepped down effective July 16, 2026, to pursue other opportunities. The company clarified that his departure was not the result of any disagreement regarding operations, policies, or practices.
Stephen Mollichella, Senior Vice President and Controller, was appointed as Interim Principal Financial Officer. Mollichella joined the company in 2021 and has led financial accounting, reporting, systems, and controls. The company is conducting a search for a permanent CFO and does not expect the transition to impact its performance or momentum.
What strategies will Harmony Biosciences employ to maintain the current growth rate of WAKIX into the second half of 2026?
How will the search for a permanent CFO influence the company's financial planning and investor relations in the coming months?
Are there plans to expand the market for WAKIX beyond its current indications to drive future revenue growth?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
